FDA Approves Lilly’s Inluriyo-Verzenio Combo

FDA granted full approval on 18 September 2026 to Inluriyo (imlunestrant), Eli Lilly's oral selective estrogen receptor degrader, in combination with Verzenio (abemaciclib), the company's CDK4/6 inhibitor, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed on endocrine therapy. The approval is a standard, not accelerated, action — it carries no confirmatory-trial obligation — and it arrived paired with an expanded companion diagnostic clearance for Guardant360 CDx, the blood-based liquid biopsy test sponsors and labs will use to identify eligible patients.

The trial data behind the label

EMBER-3 was a global, randomized, open-label phase 3 trial with three arms — imlunestrant alone, investigator's-choice endocrine therapy (fulvestrant or exemestane), and imlunestrant plus abemaciclib — enrolling patients with ER-positive, HER2-negative advanced breast cancer previously treated with an aromatase inhibitor, with or without a CDK4/6 inhibitor. Today's approval rests specifically on the ESR1-mutated subgroup, where the combination roughly doubled median progression-free survival over imlunestrant alone: 11.1 months (95% CI 7.4-13.7) versus 5.5 months (95% CI 3.8-7.2). That figure is distinct from — and should not be confused with — the trial's broader intent-to-treat population result, which showed a smaller gap; the label and this approval are specific to patients whose tumors carry an ESR1 mutation, which is precisely why the companion diagnostic matters as much as the drug combination itself.

A liquid biopsy does the gatekeeping

The label conditions use of the combination on confirming an ESR1 mutation with an FDA-authorized test, and Guardant360 CDx — a blood draw rather than a tumor biopsy — is now cleared for that role. ESR1 mutations frequently arise as tumors develop resistance to earlier endocrine therapy, which makes a blood-based test operationally convenient: re-biopsying a metastatic tumor is invasive and not always feasible, while a liquid biopsy can be repeated as a patient's disease evolves. FDA's recent moves to ease the regulatory path for cancer companion diagnostics generally are part of the same backdrop: as targeted oncology therapies proliferate, the diagnostic tests that gate access to them are drawing as much regulatory attention as the drugs themselves.

Safety and what sponsors should track

Diarrhea was the most common adverse event on the combination arm in EMBER-3, and the label carries warnings for low white blood cell counts, interstitial lung disease and pneumonitis, liver toxicity, and venous thromboembolism — a safety profile consistent with abemaciclib's existing class-wide warnings as a CDK4/6 inhibitor rather than a new signal specific to the combination. Lilly is positioning the regimen as fully oral, requiring no infusion-center visits for either agent. For RA teams, the faster story here is regulatory speed: Inluriyo moved from its first monotherapy approval to this doublet approval in about a year, on the strength of an already-established safety database — a pattern likely to recur as sponsors file combination label expansions built on drugs that already have a full first-line approval behind them.

Frequently asked questions

What did FDA approve on 18 September 2026?

Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated, locally advanced or metastatic breast cancer whose disease progressed on at least one prior line of endocrine therapy. It is a full approval, not an accelerated one.

What evidence supported the combination?

EMBER-3, a randomized phase 3 trial. In the ESR1-mutated subgroup, median progression-free survival was 11.1 months for the combination versus 5.5 months for imlunestrant alone.

What companion diagnostic is tied to this approval?

FDA simultaneously approved an expanded indication for Guardant360 CDx, a blood-based liquid biopsy test, to identify ESR1-mutated patients eligible for the combination.

Was Inluriyo already approved for something?

Yes. FDA first approved Inluriyo as monotherapy for the same ESR1-mutated population in September 2025. This action adds the abemaciclib combination about a year later.